Orchid Pharma reported a 26% year-on-year growth in PAT for Q2 2024-25, with sales reaching Rs 222.7 crores and EBITDA at Rs 37.5 crores, driven by new product launches and market expansion strategies.
AI Assistant
Orchid Pharma Ltd
2024
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.